Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NMDA Receptor Modulation for Hyperarousal in PTSD

Trial Profile

NMDA Receptor Modulation for Hyperarousal in PTSD

Phase of Trial: Phase I

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Lanicemine (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Dec 2018 Planned End Date changed from 31 Dec 2019 to 31 Oct 2019.
    • 26 Dec 2018 Planned primary completion date changed from 1 Jun 2019 to 30 Sep 2019.
    • 26 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top